Nonsteroidal anti-inflammatory drugs and the risk of nonmelanoma skin cancer

International Journal of Cancer

Volumn 137, Issue 1, 2015, Pages 144-153

  Reinau, Daphne ^a,b   Surber, Christian ^b,c   Jick, Susan S ^d   Meier, Christoph R ^a,b,d  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

basal cell carcinoma; case control analysis; nonmelanoma skin cancer; nonsteroidal anti inflammatory drugs; squamous cell carcinoma

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGE; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; FEMALE; GENDER; GENERAL PRACTICE; HUMAN; INCIDENTALOMA; MAJOR CLINICAL STUDY; MALE; NON MELANOMA SKIN CANCER; POPULATION BASED CASE CONTROL STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SQUAMOUS CELL CARCINOMA; UNITED KINGDOM; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CASE CONTROL STUDY; FACTUAL DATABASE; MIDDLE AGED; SKIN NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DATABASES, FACTUAL; FEMALE; GREAT BRITAIN; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; SKIN NEOPLASMS;

EID: 84930416568     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29357     Document Type: Article

References (35)

1. Conaghan PG,. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int 2012; 32: 1491-502.
2. Fischer SM, Hawk ET, Lubet RA,. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prevention Res 2011; 4: 1728-35.
3. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009; 10: 501-7.
4. Prado R, Francis SO, Mason MN, et al. Nonmelanoma skin cancer chemoprevention. Dermatol Surg 2011; 37: 1566-78.
5. Liebman TN, Stein JA, Polsky D,. Cyclo-oxygenase-2 inhibitors for chemoprevention of nonmelanoma skin cancer: is there a role for these agents? J Am Acad Dermatol 2013; 68: 173-6.
6. Asgari M, White E, Chren MM,. Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma. Dermatol Surg 2004; 30: 1335-42.
7. Muller-Decker K,. Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence. Cancer Metastasis Rev 2011; 30: 343-61.
8. Rundhaug JE, Fischer SM,. Cyclo-oxygenase-2 plays a critical role in UV-induced skin carcinogenesis. Photochem Photobiol 2008; 84: 322-9.
9. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinogenesis 1999; 25: 231-40.
10. Orengo IF, Gerguis J, Phillips R, et al. Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. Arch Dermatol 2002; 138: 751-5.
11. Pentland AP, Schoggins JW, Scott GA, et al. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999; 20: 1939-44.
12. Wilgus TA, Koki AT, Zweifel BS, et al. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol Carcinogenesis 2003; 38: 49-58.
13. Mikulec CD, Rundhaug JE, Simper MS, et al. The chemopreventive efficacies of nonsteroidal anti-inflammatory drugs: the relationship of short-term biomarkers to long-term skin tumor outcome. Cancer Prevent Res 2013; 6: 675-85.
14. Gupta AK, Paquet M, Villanueva E, et al. Interventions for actinic keratoses. Cochrane Database Syst Rev 2012; 12: CD004415.
15. Elmets CA, Viner JL, Pentland AP, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2010; 102: 1835-44.
16. Tang JY, Aszterbaum M, Athar M, et al. Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. Cancer Prevent Res 2010; 3: 25-34.
17. Parkinson J, Davis S, Van Staa T,. The general practice research database: now and the future. In:, Mann RD, Andrews EB, eds. Pharmacovigilance, 2nd edn. Wiley: Chichester, 2007. 341-8.
18. Williams T, Van Staa T, Puri S, et al. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf 2012; 3: 89-99.
19. Wood L, Martinez C,. The general practice research database: role in pharmacovigilance. Drug Safety 2004; 27: 871-81.
20. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69: 4-14.
21. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-9.
22. Khan NF, Harrison SE, Rose PW,. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Practice 2010; 60: e128-36.
23. Meal A, Leonardi-Bee J, Smith C, et al. Validation of THIN data for non-melanoma skin cancer. Quality Primary Care 2008; 16: 49-52.
24. Johannesdottir SA, Chang ET, Mehnert F, et al. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer 2012; 118: 4768-76.
25. Butler GJ, Neale R, Green AC, et al. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol 2005; 53: 966-72.
26. Clouser MC, Roe DJ, Foote JA, et al. Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial. Pharmacoepidemiol Drug Safety 2009; 18: 276-83.
27. de Vries E, Trakatelli M, Kalabalikis D, et al. Known and potential new risk factors for skin cancer in European populations: a multicentre case-control study. Br J Dermatol 2012; 167: 1-13.
28. Grau MV, Baron JA, Langholz B, et al. Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer 2006; 119: 682-6.
29. Torti DC, Christensen BC, Storm CA, et al. Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study. J Am Acad Dermatol 2011; 65: 304-12.
30. Vogel U, Christensen J, Wallin H, et al. Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res 2007; 617: 138-46.
31. An KP, Athar M, Tang X, et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 2002; 76: 73-80.
32. Elwood PC, Gallagher AM, Duthie GG, et al. Aspirin, salicylates, and cancer. Lancet 2009; 373: 1301-9.
33. Harris RE,. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009; 17: 55-67.
34. Moore DE,. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Safety 2002; 25: 345-72.
35. Meier CR, Schmitz S, Jick H,. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 2002; 22: 303-9.